Übersicht: Defence Therapeutics Inc.
| Datum | Publikationsart | Rating | Kurs bei Erstellung in € | Kursziel in € | Interessens- konflikt |
| 16.05.2022 | Equity Research Report (english) | k.A. | k.A. | k.A. | 5a;7;11 |
| 16.05.2022 | Equity Research Einzelstudie | k.A. | k.A. | k.A. | 5a;7;11 |
| 15.02.2022 | Equity Research Einzelstudie | kaufen | k.A. | 7,60 | 5a;5b;6a;7;11 |
| 14.02.2022 | Equity Research Einzelstudie | k.A. | k.A. | k.A. | 5a;5b;6a;7;11 |
| 14.02.2022 | Equity Research Report (english) | k.A. | k.A. | k.A. | 5a;5b;6a;7;11 |
| 10.02.2022 | Equity Research Report (english) | kaufen | k.A. | 7,60 | 5a;5b;6a;7;11 |
| 25.01.2022 | Equity Research Einzelstudie | k.A. | k.A. | k.A. | 5a;7;11 |
| 24.01.2022 | Equity Research Report (english) | k.A. | k.A. | k.A. | 5a;11;7 |
| 07.12.2021 | Analysteninterview | k.A. | k.A. | k.A. | 5a;5b;7;11 |
| 06.12.2021 | Analyst Interview (english) | k.A. | k.A. | k.A. | 5a;5b;7;11 |